Alumis Inc.

Address: 280 East Grand Avenue

Sponsor Overview

assignment

Specializations

Autoimmune Disease Research

Alumis Inc. focuses on clinical research in systemic lupus erythematosus, with interest in disease activity, immune-mediated inflammation, and clinical outcomes assessed through BILAG-based measures.

Systemic lupus erythematosus
Autoimmune disease activity
Inflammatory disease control

The sponsor’s lupus research is centered on therapeutic approaches aimed at reducing active disease burden and improving patient response in a chronic rheumatologic condition.

Dermatology and Psoriasis

The company also funds studies in moderate to severe plaque psoriasis, addressing persistent skin inflammation, lesion control, and treatment durability in a major dermatologic indication.

Moderate to severe plaque psoriasis
Skin inflammation
Chronic plaque disease

Clinical interest in psoriasis includes both symptom reduction and longer-term maintenance of disease control across ongoing treatment programs.

Immunology and Targeted Therapy

Alumis Inc. is engaged in research around immune-modulating therapies for autoimmune and inflammatory disorders, with a therapeutic emphasis on precision approaches to disease management.

Immune modulation
Inflammatory pathway targeting
Therapeutic selectivity

This area reflects the sponsor’s involvement in developing treatments intended for conditions driven by dysregulated immune activity.

Clinical Safety and Long-term Tolerability

Across its active studies, the sponsor places emphasis on safety, tolerability, and sustained treatment response in chronic immune-mediated diseases.

Safety monitoring
Tolerability assessment
Durability of response

These research interests support evaluation of treatments used over extended periods in both dermatologic and systemic autoimmune settings.

Sponsored Trials

Trial Name	Country	Status
A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Efficacy, and Pharmacokinetics of Multiple Dose Levels of ESK-001 in Adult Patients with Systemic Lupus Erythematosus	Bulgaria Croatia Denmark Germany Hungary Poland Romania Spain	Not Recruiting
Long-term Safety, Efficacy, and Response Durability of Envudeucitinib in Moderate to Severe Plaque Psoriasis: An Extension Study	Austria Belgium Bulgaria Czechia Estonia France Germany Hungary Latvia Poland Portugal Romania Spain	Not Recruiting
Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of ESK-001 and Apremilast in Moderate to Severe Plaque Psoriasis Patients	Austria Estonia France Germany Hungary Latvia Poland Romania Spain	Not Recruiting
Phase 3 Study to Evaluate the Efficacy and Safety of ESK-001 in Patients with Moderate to Severe Plaque Psoriasis	Belgium Bulgaria Czechia Germany Poland Portugal	Not Recruiting